This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
patients were randomised, 42 to usual care and 43 to CRT.
Study design
The authors conducted a single-blind, multi-centre, randomised controlled trial. An independent statistician randomly allocated the participants using a concealed randomisation method. A psychiatrist unaware of group allocation, and based in a different building to other researchers and the independent site of randomisation, rated the participants' symptoms. The participants agreed not to reveal their group allocation prior to each symptom assessment and none did so. Independent assessors initially masked to group allocation, although some participants revealed their allocation at the post-treatment assessment, collected cognitive data. Social behaviour data were collected from keyworkers or relative informants who were independent of the trial but not masked to treatment allocation. Follow-up lasted 6 months beyond treatment discontinuation.
In the treatment group, 4 (9%) patients left during the study, while post-treatment, 6 patients left and 1 returned. This equated to a loss to follow-up of 5 patients (12%). In the usual care group, 3 (7%) patients left during the study, while post-treatment 5 (12%) patients were lost to follow-up.
Analysis of effectiveness
Effectiveness was assessed at 14 weeks (post-therapy) and at 40 weeks (6 months post-therapy discontinuation). The three main outcome measures were: cognitive flexibility (categories achieved from the Wisconsin Card Sorting Test, WCST); planning (profile score from the Behavioural Assessment of the Dysexecutive Syndrome); and working memory (total raw score on the Digit Span test of the Wechsler Adult Intelligence Scale III, WAIS-III).
Data on symptoms (Positive and Negative Symptom Scale, PANSS), self-esteem (Rosenberg Self-Esteem Scale) and level of social functioning (Social Behaviour Scale) were also collected. An intention to treat approach was used. Findings were further analysed using linear mixed models. These models included baseline outcome measures and symptoms that may possibly affect cognitive outcome post therapy as explanatory variables, and the experimental factors as fixed variables.
Effectiveness results
Working memory showed an improvement across both post-treatment time points, with an estimated advantage to CRT of 1.33 (95% confidence interval, CI: 0.43 to 2.16), (standardised effect size 0.34, 95% CI: 0.1 to 0.55).
Cognitive flexibility was insignificant at 14 weeks but showed an improvement at the 6-month follow-up, with an estimated advantage to CRT of 1 (95% CI: 0.17 to 8.0), (standardised effect size 0.47, 95% CI: 0.08 to 3.77).
These results correspond to a number-needed-to-treat (NNT) for working memory of 3.1 to produce a clinical change of at least 2 points on the Digit Span test, and an NNT of 6.7 for cognitive flexibility to improve by at least two categories on the WCST.
No other statistically significant changes were found in the primary or secondary end points.
When drug effects were investigated, the results suggested that CRT had an effect on planning for those who received clozapine or typical medications. This effect was absent for patients receiving other atypical medications.
No statistically significant effect was found in terms of the proportion of patients achieving normal range scores in each of the primary end points.
Clinical conclusions
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The authors concluded that there was a durable improvement in working memory, a significant improvement in cognitive flexibility, and a non significant advantage in planning. Thus, CRT had demonstrated overall effectiveness in a mixed group of participants.
Measure of benefits used in the economic analysis
The measure of benefit used was the percentage of improvers in each group based on WAIS-III Digit Span raw scores, improvers being defined as gaining 2 or more points since baseline.
Direct costs
Health, social care and criminal justice system resource use were assessed using the Client Service Receipt Inventory retrospectively from health care staff or records, and/or by participant self-report for the relevant assessment intervals. Details of the included costs were not reported, and the costs and the quantities were not addressed separately. The unit costs at 2000/01 levels were based on national statistics. Discounting was not relevant.
Statistical analysis of costs
Mean costs (with standard deviations, SDs) by treatment group, both during the treatment period and at the final follow-up, were reported for health/social care costs and societal costs. Differences in mean costs and 95% CIs were calculated using bootstrap techniques.
Indirect Costs
Societal costs were reported as the total per patient costs only. No details of the methods or sources were provided.
Currency
UK pounds sterling ().
Sensitivity analysis
For the cost-effectiveness results, the percentages of improvers were compared using non-parametric bootstrapping, adjusted for baseline WAIS-III Digit Span raw score and total PANSS score.
Estimated benefits used in the economic analysis
It was stated that at the post-treatment evaluation, a mean difference of 21% of patients showed cognitive improvement in the CRT group (95% CI: 0 to 41), while at the 6-month follow-up, a mean difference of 21% of patients showed improvement (95% CI: 2 to 41).
Cost results
For the intervention group, the mean health/social care costs were 7,756 (SD=5,936) post-treatment and 15,639 (SD=12,453) at follow-up. The mean societal costs were 8,868 (SD=5,849) post-treatment and 17,586 (SD=12,197) at follow-up.
For the usual care group, the mean health/social care costs were 8,271 (SD=7,494) post-treatment and 13,426 (SD=12,852) at follow-up. The mean societal costs were 9,497 (SD=7,413) post-treatment and 15,735 (SD=12,654) at follow-up.
At post-treatment evaluation, the CRT group differed in health/social care costs by -1,086 (95% CI: -3,146 to 1,152) and in societal costs by -1,284 (95% CI: -3,348 to 942). At 6-month follow-up, the figures were 975 (95% CI: -3,330 to 5,255) and 494 (95% CI: -3,564 to 4,577), respectively.
Interpretation of the cost and effectiveness results tended to favour the intervention, although the only significant effects were in two of the primary outcomes. Given the large CIs and non significance of many of the results, the strength of the authors' conclusions regarding the benefits of CRT does not appear to be supported by the evidence.
